• Viking Therapeutics, Inc. has announced it will present two posters on its VK2735 obesity program at the 33rd European Congress on Obesity in Istanbul on May 12–15, 2026, including Phase 2 VENTURE-Oral efficacy and safety data and Phase 3 VANQUISH-1 trial design details.
• This upcoming disclosure of oral and subcutaneous VK2735 data highlights Viking’s push to compete with existing GLP-1 and dual GLP-1/GIP obesity treatments such as semaglutide and tirzepatide.
• We’ll now examine how the upcoming Phase 2 VENTURE-Oral data presentation for VK2735 could influence Viking Therapeutics’ longer-term investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Viking Therapeutics Investment Narrative Recap

To own Viking Therapeutics, you need to believe VK2735 can eventually earn a place alongside existing GLP-1 and dual GLP-1/GIP obesity drugs, despite the company’s lack of revenue and growing losses. The ECO poster presentations on VENTURE-Oral and VANQUISH-1 do not change the central near term catalyst, which remains the progress and eventual readouts from the Phase 3 VANQUISH program, or the key risk of trial setbacks and continued cash burn.

The most relevant recent announcement alongside the ECO news is Viking’s first quarter 2026 result, which showed a wider net loss of US$158.33 million compared with a year earlier. That growing loss underlines how dependent the investment case is on successful VK2735 development, since the company is funding Phase 3 VANQUISH trials and the oral program without any product revenue today.

Yet beneath the enthusiasm around VK2735, investors should also be aware that...

Viking Therapeutics' narrative projects $118.5 million revenue and $12.9 million earnings by 2029. This requires earnings to improve by about $372.5 million from -$359.6 million today.

Uncover how Viking Therapeutics' forecasts yield a $92.72 fair value, a 187% upside to its current price.

Exploring Other Perspectives

Some analysts take a far more optimistic view than consensus, tying this ECO data to a story where VK2735 underpins US$497.5 million of revenue and US$62.2 million of earnings by 2029, while others see the same trial and cash burn risks from very different angles.

Explore 16 other fair value estimates on Viking Therapeutics - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Viking Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Viking Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Therapeutics' overall financial health at a glance.

Want Some Alternatives?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Find 44 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.